Recursion Pharmaceuticals Inc
$ 3.54
3.51%
14 Apr - close price
- Market Cap 1,806,452,000 USD
- Current Price $ 3.54
- High / Low $ 3.55 / 3.46
- Stock P/E N/A
- Book Value 2.14
- EPS -1.44
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.60 %
- 52 Week High 7.18
- 52 Week Low 2.80
About
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is headquartered in Salt Lake City, Utah.
Analyst Target Price
$6.71
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-05 | 2025-08-05 | 2025-05-07 | 2025-02-25 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-02-27 | 2023-11-09 | 2023-08-08 | 2023-05-08 |
| Reported EPS | -0.21 | -0.36 | -0.41 | -0.5 | -0.53 | -0.34 | -0.4 | -0.39 | -0.42 | -0.43 | -0.38 | -0.34 |
| Estimated EPS | -0.3 | -0.37 | -0.35 | -0.516 | -0.4168 | -0.35 | -0.4 | -0.42 | -0.45 | -0.38 | -0.37 | -0.35 |
| Surprise | 0.09 | 0.01 | -0.06 | 0.016 | -0.1132 | 0.01 | 0 | 0.03 | 0.03 | -0.05 | -0.01 | 0.01 |
| Surprise Percentage | 30% | 2.7027% | -17.1429% | 3.1008% | -27.1593% | 2.8571% | 0% | 7.1429% | 6.6667% | -13.1579% | -2.7027% | 2.8571% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.27 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RXRX
2026-04-10 13:10:00
Recursion Pharmaceuticals (RXRX) saw a 10.8% increase after announcing an expanded partnership with Citeline to integrate real-world data into its AI-enabled ClinTech Platform. This collaboration aims to enhance clinical trial design and site selection, broadening the role of Recursion's AI platform beyond drug discovery. The company seeks to make its technology more relevant to partners and pipeline programs, potentially impacting its investment narrative.
2026-04-03 16:39:07
Recursion Pharmaceuticals (RXRX) recently expanded its partnership with Citeline for AI-powered drug development and appointed Vicki Goodman, M.D., as its new Chief Medical Officer, effective April 6, 2026. These moves aim to strengthen clinical execution, especially in oncology. While these developments are seen as positive for near-term clinical studies, the company still faces significant cash burn, a limited cash runway into late 2027, and reliance on external funding.
2026-04-02 06:10:03
Recursion Pharmaceuticals (RXRX) is experiencing divergent investor narratives regarding its valuation, with some investors finding it overvalued at $3.07 based on a fair value of $1.97, while Simply Wall St's DCF model suggests it is undervalued with a fair value of $9.54. The article highlights the company's clinical stage pipeline and revenue, prompting investors to scrutinize the numbers and warnings before making investment decisions.
2026-03-29 04:40:02
The Vanguard Group filed an amended Schedule 13G/A for Recursion Pharmaceuticals Inc (RXRX), reporting 0 beneficial shares and 0% ownership. This change is due to an internal realignment within Vanguard, leading to disaggregated reporting by its subsidiaries, as per SEC Release No. 34-39538. The filing clarifies that this does not indicate a sale of shares but rather a restructuring of how Vanguard's holdings are reported by its various entities.
2026-03-26 19:39:26
Recursion Pharmaceuticals has appointed Vicki Goodman, M.D., as its new Chief Medical Officer, bringing over 20 years of oncology drug development experience. This appointment is significant given Recursion's recent weak share performance and its clinical pipeline nearing key decision points. Investors will be watching closely to see how Dr. Goodman's expertise translates into improved trial design, regulatory interactions, and resource allocation, potentially influencing the company's path forward despite facing execution risks.
2026-03-26 13:39:26
RECURSION PHARMACEUTICALS, INC. director Christopher Gibson converted 40,000 shares of Class B Common Stock into Class A Common Stock and subsequently sold these 40,000 Class A shares at $3.25 each through an open-market transaction under a Rule 10b5-1 trading plan. After these transactions, Gibson directly holds 906,556 shares of Class A Common Stock and 4,483,334 shares of Class B Common Stock. The filing also details various derivative securities and stock options held by Gibson, along with their vesting schedules and beneficial ownership entities.
